From 1975 until 1984 37 children with newly diagnosed Hodgkin's disease were treated with six mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) courses with or without involved field radiotherapy (25 Gy) independent of the stage of their disease. Patients with small lymph node tumors (less than 4 cm) received only six MOPP-courses. Patients with large lymph node tumors (greater than 4 cm) received involved field radiotherapy, 25 Gy to the large tumor masses, between the third and fourth MOPP-course. For the 21 patients with "small" tumors, the disease-free survival (DFS) rate is 90%. In this group two patients with clinical stage (CS) III disease have relapsed but both are alive after successful salvage treatment. The median follow-up time is 69.7+ months. For the 16 patients with larger tumor masses (greater than 4 cm) the DFS rate is 87.5%. In this group one patient with CS II relapsed and died of Hodgkin's disease, and one with CS III relapsed after 37 months, but is now without evidence of disease, 61 months from diagnosis. The median follow-up time is 62+ months. Most of the children with Hodgkin's disease diagnosed before or during puberty can be cured with chemotherapy alone, and thus will not suffer from the damaging late effects of radiotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1002/1097-0142(19870601)59:11<1870::aid-cncr2820591105>3.0.co;2-dDOI Listing

Publication Analysis

Top Keywords

hodgkin's disease
16
involved field
8
field radiotherapy
8
lymph node
8
node tumors
8
tumor masses
8
dfs rate
8
median follow-up
8
follow-up time
8
disease
7

Similar Publications

Background: Disseminated nocardiosis is a rare and potentially fatal disease, with a higher incidence in immunocompromised patients, such as those living with human immunodeficiency virus (HIV) or hematological malignancies, including lymphoma. Information on Nocardia spp. infection in Venezuela is limited.

View Article and Find Full Text PDF

Background and objective Lymphomas can involve the gastrointestinal (GI) tract as a primary disease or as a secondary spread of systemic disease. The GI tract is a key site for extranodal lymphomas, with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) occurring in this region. This study aimed to analyze the demography, anatomic distribution, histological subtypes, and immunomorphological characteristics of all lymphomas with a primary GI presentation at a quaternary care hospital in southern India.

View Article and Find Full Text PDF

Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma rarely presents with circulating lymphoma cells (CL) at diagnosis. Previous studies were limited by small sample size precluding robust analysis. Hence, we evaluated the prognostic relevance of CL cells in newly diagnosed DLBCL patients.

View Article and Find Full Text PDF

Clinical features and temporal trends in H. pylori negative gastric maltoma.

Arab J Gastroenterol

January 2025

Division of Gastroenterology and Hepatology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address:

Article Synopsis
  • Mucosa-Associated Lymphoid Tissue (MALT) lymphoma, particularly gastric MALToma, is often associated with Helicobacter pylori (H. pylori) infection, though a significant number of cases occur without it.
  • A study analyzed 52 patients with gastric MALToma from 2000 to 2021, finding that 48.1% were H. pylori-negative (HPN) and noted trends of increased HPN diagnoses in more recent years.
  • Treatment outcomes showed that HPP patients had better responses to eradication therapy compared to HPN patients, who were more likely to receive additional chemo or radiotherapy.
  • Despite these differences in treatment response, clinical features between HPP and HPN patients
View Article and Find Full Text PDF

Follicular lymphoma (FL) represents the second most frequent type of non-Hodgkin lymphoma and the most common indolent histology. The disease course of FL is heterogeneous, likely resulting from diverse molecular and immunological features that drive a broad spectrum of clinical presentations. While some patients with low-volume and asymptomatic disease are suitable for observation, patients with high tumor burden, advanced-stage, or symptomatic disease more often necessitate treatment initiation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!